Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: Role of dopamine, serotonin and glutamate candidate genes

Pharmacogenomics Journal

Volumn 16, Issue 5, 2016, Pages 439-445

  Mas, S ^a,b,c   Gasso P ^a,b,c   Lafuente, A ^a,b,c   Bioque, M ^b,c,d   Lobo, A ^c,e   Gonzalez Pinto A ^c,f   Olmeda, M S ^g   Corripio, I ^c,h   Llerena, A ⁱ   Cabrera, B ^b,c,d   Saiz Ruiz, J ^c,j   Bernardo, M ^a,b,c,d   Mezquida, Gisela ^b,c,d   Meseguer, Ana ^b,c,d   Bernardo, Enrique García ^g   Parellada, Mara ^c,g   Alonso Solís, Anna ^c,h   Grasa, Eva ^c,h   Hernandez, Miryam ^c,f   Cengotitabengoa, Monica Martinez ^c,f   Barcones, Fe ^c,e   Arbej, Julio ^c,e   Sanjuan, Julio ^c,g   Aguilar, Eduardo J ^c,g   Balbuena, Antonio ^c,k,l   Mané, Anna ^c,k,l   Torrent, Carla ^b,l   Vieta, Eduard ^b,l   Baeza, Immaculada ^a,b   de la Serna, Elena ^a,b   Contreras, Fernando ^c,d,m   Albacete, Auria ^c,d,m   García Portilla, Maria Paz ^a,c   Bobes, Julio ^a,c   Rabadán, Arantzazu Zabala ^c,n   Echevarría, Rafael Segarra ^c,n,o   Morales Muñoz, Isabel ^c,p   Rodriguez Jimenez, Roberto ^c,p   Butjosa, Anna ^c,q   Rodie, Judith Usall ^c,q   Sarró, Salvador ^r   Landín Romero, Ramón ^r   Cuadrado, Angela Ibañez ^c,j   Cuesta, Manuel J ^s,t   Balanzá Martínez, Vicent ^c,k,u   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY OF ZARAGOZA   (Spain)

^f HOSPITAL TXAGORRITXU   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ UNIVERSITY OF EXTREMADURA   (Spain)

^j UNIVERSITY OF ALCALÁ   (Spain)

^k UNIVERSITY OF VALENCIA   (Spain)

^l HOSPITAL DEL MAR   (Spain)

^m HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁿ UNIVERSITY OF OVIEDO   (Spain)

^o UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^p HOSPITAL DE CRUCES   (Spain)

^q Bellvitge University Hospital IDIBELL ^*  (Spain)

^r PARC SANITARI SANT JOAN DE DÉU   (Spain)

^s FIDMAG GERMANES HOSPITALÀRIES RESEARCH FOUNDATION   (Spain)

^t Universidad Pública de Navarra   (Spain)

^u Recinto de Complejo Hospitalario de Navarra   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; DOPAMINE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; NEUROLEPTIC AGENT; PALIPERIDONE; RISPERIDONE; SEROTONIN; VESICULAR MONOAMINE TRANSPORTER 2; ZIPRASIDONE; DRD2 PROTEIN, HUMAN; GLUK3 KAINATE RECEPTOR; KAINIC ACID RECEPTOR; SEROTONIN 2A RECEPTOR; SLC18A2 PROTEIN, HUMAN; VESICULAR MONOAMINE TRANSPORTER;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRD2 GENE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; GENDER; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPE PHENOTYPE CORRELATION; GRIK3 GENE; HAPLOTYPE; HTR2A GENE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT RISK; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN PROTEIN INTERACTION; PSYCHOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SLC18A2 GENE; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLINICAL TRIAL; EXTRAPYRAMIDAL SYNDROME; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHARMACOGENETIC VARIANT; PHENOTYPE; PSYCHOTIC DISORDERS; RISK ASSESSMENT; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CASE-CONTROL STUDIES; CHILD; DOPAMINE; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GLUTAMIC ACID; HAPLOTYPES; HUMANS; LONGITUDINAL STUDIES; MALE; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, KAINIC ACID; RISK ASSESSMENT; RISK FACTORS; SEROTONIN; SPAIN; TREATMENT OUTCOME; VESICULAR MONOAMINE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 84976330756     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2016.44     Document Type: Article

References (50)

1. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-Analysis. Lancet 2013; 382: 951-962
2. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-Analysis of head-To-head comparisons. Schizophr Bull 2012; 38: 167-177
3. Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int 2014; 2014: 656370
4. Dolzan V, Plesnicar BK, Serretti A, Mandelli L, Zalar B, Koprivsek J, et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-Term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 809-815
5. Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gassó P, et al. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophr Res 2007; 90: 115-122
6. Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gassó P, et al. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatry Res 2008; 161: 131-141
7. Greenbaum L, Strous RD, Kanyas K, Merbl Y, Horowitz A, Karni O, et al. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet Genomics 2007; 17: 519-528
8. Gassó P, Mas S, Bernardo M, Alvarez S, Parellada E, Lafuente A. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J 2009; 9: 404-410
9. Lawford BR, Barnes M, Swagell CD, Connor JP, Burton SC, Heslop K, et al. DRD2/ANKK1 Taq1A (rs 1800497 C4T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia. J Psychopharmacol 2013; 27: 343-348
10. Zivkovic M, Mihaljevic-Peles A, Bozina N, Saqud M, Nikolac-Perkovic M, Vuksan-Cusa B, et al. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. J Clin Psychopharmacol 2013; 33: 593-599
11. Güzey C, Scordo MG, Spina E, Landsem VM, Spigset O. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol 2007; 63: 233-241
12. Gunes A, Scordo MG, Jaanson P, Dahl ML. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazinetreated schizophrenic patients. Psychopharmacol (Berl) 2007; 190: 479-484
13. Gunes A, Dahl ML, Spina E, Scordo MG. Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 2008; 64: 477-482
14. Al-Janabi I, Arranz MJ, Blakemore AI, Saiz PA, Susce MT, Glasser PE, et al. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr Genet 2009; 19: 305-311
15. Wilffert B, Al Hadithy AF, Sing VJ, Matroos G, Hoek HW, Van Os J, et al. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African - Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX. J Psychopharmacol 2009; 23: 652-659
16. Creed-Carson M, Oraha A, Nobrega JN. Effects of 5-HT(2 A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats. Behav Brain Res 2011; 219: 273-279
17. Giegling I, Drago A, Dolžan V, Plesnicar BK, Schäfer M, Hartmann AM, et al. Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. Pharmacogenet Genomics 2011; 21: 206-216
18. Drago A, Giegling I, Schäfer M, Hartmann AM, Möller HJ, De Ronchi D, et al. No association of a set of candidate genes on haloperidol side effects. PLoS One 2012; 7: e44853
19. Drago A, Giegling I, Schäfer M, Hartmann AM, Möller HJ, De Ronchi D, et al. AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. Eur Neuropsychopharmacol 2013; 23: 887-894
20. Tybura P, Trzesniowska-Drukala B, Bienkowski P, Beszlej A, Frydecka D, Mierzejewski P, et al. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine. Psychiatry Res 2014; 219: 261-267
21. Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Vaquero-Lorenzo C, Fernandez-Piqueras J, et al. CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics 2013; 23: 627-630
22. Aberg K, Adkins DE, Bukszár J, Webb BT, Caroff SN, Miller DD, et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010; 67: 279-282
23. Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacol (Berl) 2009; 206: 491-499
24. Drago A, Crisafulli C, Serretti A. The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 975-986
25. Haddad PM, Das A, Keyhani S, Chaudhry IB. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol 2012; 26: 15-26
26. Bernardo M, Bioque M, Parellada M, Saiz Ruiz J, Cuesta MJ, Llerena A, et al. Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). Rev Psiquiatr Salud Ment 2013; 6: 4-16
27. American Psychiatric Association (Washington). DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC, USA, 1994
28. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a crosssectional study of side effects in neuroleptic-Treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100
29. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19
30. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686-693
31. González JR, Armengol L, Solé X, Guinó E, Mercader JM, Estivill X, et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007; 23: 644-645
32. Jakulin A, Bratko I. Analyzing attribute interactions. Lect Notes Artif Intell 2003; 2838: 229-240
33. Hedenmalm K, Güzey C, Dahl ML, Yue QY, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006; 26: 192-197
34. Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, et al. Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin 2006; 27: 966-970
35. Kaiser R, Tremblay PB, Klufmöller F, Roots I, Brockmöller J. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 2002; 7: 695-705
36. Zai CC, Hwang RW, De Luca V, Müller DJ, King N, Zai GC, et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007; 10: 639-651
37. Bakker PR, Van Harten PN, Van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a metaanalysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13: 544-556
38. Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 2012; 34: 1487-1504
39. Tsai HT, Caroff SN, Miller DD, McEvoy J, Lieberman J, North KE, et al. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 336-340
40. Zai CC, Tiwari AK, Mazzoco M, De Luca V, Müller DJ, Shaikh SA, et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res 2013; 47: 1760-1765
41. Al Hadithy AF, Wilffert B, Stewart RE, Looman NM, Bruggeman R, Brouwers JR, et al. Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African - Caribbean inpatients: differences in association with dopamine and serotonin receptors. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 890-897
42. Bakker PR, Bakker E, Amin N, Van Duijn CM, Van Os J, Van Harten PN. Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PLoS One 2012; 7: e36561
43. Knol W, Van Marum RJ, Jansen PA, Strengman E, Al-Hadithy AF, Wilffert B, et al. Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach. J Clin Psychopharmacol 2013; 33: 405-410
44. Laje G, Cannon DM, Allen AS, Klaver JM, Peck SA, Liu X, et al. Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int J Neuropsychopharmacol 2010; 13: 715-724.
45. Crowley JJ, Kim Y, Szatkiewicz JP, Pratt AL, Quackenbush CR, Adkins DE, et al. Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm Genome 2012; 23: 322-335
46. Ivanova SA, Loonen AJ, Pechlivanoglou P, Freidin MB, Al-Hadithy AF, Rudikov EV, et al. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Transl Psychiatry 2012; 2: e67
47. Syu A, Ishiguro H, Inada T, Horiuchi Y, Tanaka S, Ishikawa M, et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacol 2010; 35: 1155-1164
48. Greenbaum L, Alkelai A, Zozulinsky P, Kohn Y, Lerer B. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J 2012; 12: 513-520
49. Mas S, Llerena A, Saíz J, Bernardo M, Lafuente A. Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics 2012; 13: 1773-1782
50. Mas S, Gassò P, Alvarez S, Parellada E, Bernardo M, Lafuente A. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J 2012; 12: 255-259